APTIVUS (tipranavir) by Boehringer Ingelheim is hiv protease inhibitors [moa]. Approved for protease inhibitor [epc]. First approved in 2005.
Drug data last refreshed 20h ago
HIV Protease Inhibitors
Protease Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers
A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.
Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers
Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients
Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects
Worked on APTIVUS at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.